JMP Securities Maintains Market Outperform on Ocular Therapeutix, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has maintained a Market Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) and doubled the price target from $12 to $24. This adjustment reflects a positive outlook on the company's future performance.
March 12, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has maintained a Market Outperform rating on Ocular Therapeutix and raised the price target from $12 to $24, indicating a strong positive outlook on the company's future performance.
The doubling of the price target by a reputable analyst firm like JMP Securities is a strong vote of confidence in Ocular Therapeutix's future prospects. This significant increase in the price target is likely to generate positive investor sentiment and could lead to a short-term increase in the stock price, as it reflects expectations of strong future performance and potential upside.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100